From Science Daily:
An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial by researchers at Dana-Farber Cancer Institute. Individuals who received the drug, cabozantinib, had a longer time to progression — the interval before their cancer worsened — than those taking sunitinib (Sutent), the drug that has been the standard initial treatment for metastatic kidney cancer for the past decade.
Read the full article.
